GlassScriptPhysician profile
Marissa Wagner
NPI 1033882907
$705.33
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $360 · 2022: $346.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $281.22 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $72.76 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $65.94 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $56.60 | 2021 | |
| Vivus LLC | $55.36 | 2021-2022 | |
| Ucb, INC. | $48.63 | 2021-2022 | |
| Intercept Pharmaceuticals, INC. | $35.53 | 2021-2022 | |
| Ironwood Pharmaceuticals, INC | $30.74 | 2021-2022 | |
| Gilead Sciences, INC. | $25.11 | 2022 | |
| Qol Medical, LLC | $18.24 | 2021 | |
| Daiichi Sankyo INC. | $15.20 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marissa Wagner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.